To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor.
Age range
54 Years – 75 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Red blood cell flux
Timeframe: Recorded continuously for up to 4 hours during the study visit
Mean arterial pressure (mmHg)
Timeframe: Recorded continuously for up to 4 hours during the study visit
baseline plasma TNF-α concentration (pg/ml)
Timeframe: Upon participants' arrival to the first study visit up to 5 minutes
One week post-intervention plasma TNF-α concentration (pg/ml)
Timeframe: Upon participants' arrival to the second study visit (1 week after the first visit)
baseline plasma IL-1β concentration (pg/ml)
Timeframe: Upon participants' arrival to the first study visits up to 5 minutes
One week post-intervention plasma IL-1β concentration (pg/ml)
Timeframe: Upon participants' arrival to the second study visit (1 week after the first visit)
baseline plasma IL-6 concentration (pg/ml)
Timeframe: Upon participants' arrival to the first study visits up to 5 minutes
One week post-intervention plasma IL-6 concentration (pg/ml)
Timeframe: Upon participants' arrival to the second study visit (1 week after the first visit)